RCS-4

RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole, is a synthetic cannabinoid drug sold under the names SR-19, BTM-4, or Eric-4 (later shortened to E-4), but originally, OBT-199.

Pharmacology

RCS-4 is a potent cannabinoid receptor agonist, with EC₅₀ values of 146 nM for human CB₁ receptors, and 46 nM for human CB₂ receptors. All methoxyphenyl regiosiomers, and N-butyl homologues of RCS-4 and its regiosiomers also display potent agonist activities at CB₁ and CB₂ receptors.

Legality

RCS-4 was banned in Sweden on 1 October 2010 as a hazardous good harmful to health, after being identified as an ingredient in "herbal" synthetic cannabis products.

It was outlawed in Denmark on 11 March 2011.

In August 2011, New Zealand added not only RCS-4 but also its 1-butyl homologue, and the 2-methoxybenzoyl isomers of both these compounds, to a temporary class drug schedule (i.e. equivalent to Class C but reviewed after 12 months, and with personal possession and use of small amounts decriminalised), which was newly created under the Misuse of Drugs Amendment Act 2011 passed a week earlier.

RCS

RCS may refer to:

Organisations

Places

Science

Technology

Computing

Other

See also

RCS-8

RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole, is a synthetic cannabinoid also known as SR-18 or BTM-8 that has been found as an ingredient of "herbal" synthetic cannabis blends. It can be described as an analogue of JWH-250 with the 1-pentyl group replaced by 1-(2-cyclohexylethyl), and can be expected to be less potent than JWH-250 (cf. JWH-007 and its cyclohexylethyl analogue). Despite not having been reported in the scientific or patent literature as yet, reputed recreational use of RCS-8 in the United States has led to it being specifically listed in a proposed 2011 amendment to the Controlled Substances Act, aiming to add a number of synthetic drugs into Schedule I.

See also

References